Mike Poole

Dr. Poole currently serves as an advisor for Neumora Therapeutics and for Gates Ventures. He also serves on the Board of Directors for MMS and for several biotechnology companies, both public and venture-funded. 

Previously, Dr. Poole led external investments in the Office of the President for Global Health at the Bill and Melinda Gates Foundation. Prior to joining the Gates Foundation, Dr. Poole served as Vice President and head of Neuroscience Innovation at AstraZeneca. He also served as Chief Medical Officer for Link Medicine and Hypnion, and was Vice President of Neuroscience Development at Wyeth and Pfizer.

At MMS, Dr. Poole provides guidance on the design, conduct, and reporting of global phase 2-4 clinical trials, the implementation of clinical development plans, and global regulatory filings. He has supported a wide range of indications from analgesia, pain, neurology, Alzheimer’s Disease, psychiatry, infectious disease and more.

Dr. Poole earned his undergraduate degree at the University of California, Berkeley and his medical degree from the UC San Diego School of Medicine. He is board certified in internal medicine, having trained at Strong Memorial Hospital at the University of Rochester. He also is board-certified in adult neurology, completing his post-graduate training in neurology at the University of Michigan.

In his free time, he can often be found sailing the waters of Puget Sound, enjoying the incredible scenery.

Suggested For You

perspectives

October 8th, 2024

Diversity Action Plan Guidance Part I: Implications for Sponsors

webinar

October 22nd, 2024

Optimal Strategies to Protect Commercially Confidential Information (CCI) in Clinical Documents and Report Trial Results Under Revised EU-CTIS Transparency Rules

perspectives

September 30th, 2024

Meet the Leaders Driving MMS’s European Growth

perspectives

September 30th, 2024

The Future of Data Management and Biostatistics: Trends and Technologies Shaping the Industry

perspectives

September 24th, 2024

Embracing Quality Management Maturity (QMM) at the Cornerstone of the Pharmaceutical Industry

perspectives

September 11th, 2024

From Historical Precedent to Modern Approvals: Lessons Learned on OTC Drug Products for FDA OMORs

webinar

September 26th, 2024

Regulatory Pathways for Nonprescription Drugs: A Deep Dive into OTC Monograph Reform and FDA Guidance

perspectives

September 4th, 2024

Email Security – Navigating Through the Process of Validation and Compliance with Healthcare Business Stakeholders

perspectives

August 27th, 2024

Optimizing Oncology Drug Development: FDA Expedited Pathways, Real-Time Review, and Global Programs

regulatory intelligence

August 27th, 2024

Recent Guidance on Diversity Action Planning

regulatory intelligence

August 26th, 2024

Oncology Programs at the FDA

regulatory intelligence

August 26th, 2024

Three Key Take Reflections on the Recent Donanemab Approval